Vyant Bio, Inc.
VYNT
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -27.88% | -73.60% | -87.22% | -40.63% | -49.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.88% | -73.60% | -87.22% | -40.63% | -49.85% |
| Cost of Revenue | -9.21% | -63.21% | -87.13% | -44.73% | -32.14% |
| Gross Profit | -12.95% | 25.30% | 86.84% | 49.76% | -16.81% |
| SG&A Expenses | -39.86% | 29.75% | -9.06% | -14.71% | -8.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.34% | 5.04% | -9.99% | 8.52% | 9.91% |
| Operating Income | 61.58% | -11.06% | 3.15% | -12.36% | -15.14% |
| Income Before Tax | 62.43% | 1.77% | 14.04% | -11.39% | -9.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.43% | 1.77% | 14.04% | -11.39% | -9.38% |
| Earnings from Discontinued Operations | -- | 96.80% | 96.02% | 115.50% | -537.93% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.01% | 51.11% | 82.86% | 22.37% | -38.68% |
| EBIT | 61.58% | -11.06% | 3.15% | -12.36% | -15.14% |
| EBITDA | 61.21% | -12.15% | 2.80% | -14.37% | -15.19% |
| EPS Basic | 73.98% | 54.60% | 83.15% | 23.50% | -36.67% |
| Normalized Basic EPS | 65.08% | -1.26% | 10.36% | -9.77% | -12.51% |
| EPS Diluted | 73.98% | 54.60% | 83.15% | 23.50% | -36.67% |
| Normalized Diluted EPS | 65.08% | -1.26% | 10.36% | -9.77% | -12.51% |
| Average Basic Shares Outstanding | 7.58% | 7.68% | 1.75% | 1.47% | 1.46% |
| Average Diluted Shares Outstanding | 7.58% | 7.68% | 1.75% | 1.47% | 1.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |